Allbet Gaming

彩客网(www.99cx.vip):Sanofi ends cancer drug trials

Allbet登录网址 2022年08月26日 社会 3 0

彩客网www.99cx.vip)是一个开放皇冠体育网址代理APP下载、皇冠体育网址会员APP下载、皇冠体育网址线路APP下载、皇冠体育网址登录APP下载的官方平台。彩客网上彩客分析专家数据更新最快。彩客网开放皇冠官方会员注册、皇冠官方代理开户等业务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

皇冠官方网址www.99cx.vip)实时更新发布最新最快最有效的皇冠官方网址,包括皇冠官方手机网址,皇冠官方备用网址,皇冠官方最新网址,皇冠官方足球网址,皇冠官方网址大全。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。 Allbet Gaming声明:该文看法仅代表作者自己,与本平台无关。转载请注明:彩客网(www.99cx.vip):Sanofi ends cancer drug trials
发布评论

分享到:

皇冠足球网址(www.99cx.vip):Najib's defence team saddened over federal court ruling
你是第一个吃螃蟹的人
发表评论

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。